Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis
- 12 September 2015
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 14 (11) , 1737-1748
Abstract
(2015). Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opinion on Drug Safety: Vol. 14, No. 11, pp. 1737-1748. doi: 10.1517/14740338.2015.1093620Keywords
This publication has 64 references indexed in Scilit:
- Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic ReviewPLOS ONE, 2013
- MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy: Figure 1Journal of Neurology, Neurosurgery & Psychiatry, 2011
- Immune reconstitution inflammatory syndrome in natalizumab-associated PMLNeurology, 2011
- Age-Specific Seroprevalence of Merkel Cell Polyomavirus, BK Virus, and JC VirusClinical and Vaccine Immunology, 2011
- Thalamofrontal neurodevelopment in new-onset pediatric idiopathic generalized epilepsyNeurology, 2011
- JC Virus Latency in the Brain and Extraneural Organs of Patients with and without Progressive Multifocal LeukoencephalopathyJournal of Virology, 2010
- Human Polyomavirus JC (JCV) Infection of Human B Lymphocytes: A Possible Mechanism for JCV Transmigration across the Blood‐Brain BarrierThe Journal of Infectious Diseases, 2010
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- PML-IRIS in patients with HIV infectionNeurology, 2009
- Natalizumab and PMLNature Neuroscience, 2005